Edition:
India

GlaxoSmithKline Consumer Healthcare Ltd (GLSM.NS)

GLSM.NS on National Stock Exchange of India

5,939.95INR
18 May 2018
Change (% chg)

Rs8.40 (+0.14%)
Prev Close
Rs5,931.55
Open
Rs5,931.55
Day's High
Rs5,999.95
Day's Low
Rs5,926.80
Volume
39,015
Avg. Vol
18,064
52-wk High
Rs6,940.25
52-wk Low
Rs4,851.00

Select another date:

Fri, May 11 2018

BRIEF-India's Glaxosmithkline Consumer Healthcare March-Qtr Profit Rises

* MARCH QUARTER PROFIT 2.12 BILLION RUPEES VERSUS PROFIT OF 1.76 BILLION RUPEES LAST YEAR

GSK buys out Novartis in $13 billion consumer healthcare shake-up

FRANKFURT/ZURICH GlaxoSmithKline is buying Novartis out of their consumer healthcare joint venture for $13 billion, taking full control of products including Sensodyne toothpaste, Panadol headache tablets, muscle gel Voltaren, and Nicotinell patches. | Video

GSK buys out Novartis in $13 billion consumer healthcare shake-up

FRANKFURT/ZURICH GlaxoSmithKline is buying Novartis out of their consumer healthcare joint venture for $13 billion, taking full control of products including Sensodyne toothpaste, Panadol headache tablets, muscle gel Voltaren, and Nicotinell patches. | Video

UPDATE 4-GSK buys out Novartis in $13 bln consumer healthcare shake-up

* Deal unravels JV agreed in 2014 (Adds fund manager quote, background on new Novartis CEO)

MEDIA-India's GlaxoSmithKline Consumer Healthcare to enter protein supplement segment - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

BRIEF-India's GlaxoSmithKline Consumer Healthcare Dec Qtr Profit Up 20 Pct

* DEC QUARTER PROFIT 1.64 BILLION RUPEES VERSUS PROFIT OF 1.36 BILLION RUPEES LAST YEAR

BRIEF-Neurometrix, Glaxosmithkline Announce Collaboration To Develop Quell Wearable Pain Relief Technology

* NEUROMETRIX AND GLAXOSMITHKLINE CONSUMER HEALTHCARE ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND EXPAND ACCESS TO QUELL WEARABLE PAIN RELIEF TECHNOLOGY

Select another date: